Please assess the completion status of the following clinical trial:

Trial Title: LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~Subjects must meet all of the following criteria:~1. Histologically confirmed stage IV urothelial carcinoma of the bladder, upper urinary tract or urethra.~2. Prior treatment for metastatic disease with at least one cisplatin or carboplatin-based multi-agent chemotherapeutic regimen. Prior immunotherapy with anti-PD-L1 or anti-PD1 agents is allowed.~   o Chemotherapy received peri-operatively for non-metastatic bladder cancer will be considered a prior regimen if less than 24 months have elapsed since treatment.~3. Measurable disease per RECIST 1.1. See Section 10 for the evaluation of measurable disease.~4. Tissue Pre-screen: Archived tissue must have been obtained within 60 months of subject signing tissue pre-screen consent. Biopsy accessible disease if adequate archival tissue does not exist for molecular characterization.~   Treatment: Available tumor specimen C-MET/RON expression results that meet the criteria for one of the three molecularly defined cohorts per Section 4.2~5. Age ≥ 18 years~6. ECOG performance status ≤ 2~7. Adequate liver function: AST and ALT ≤ 2x upper limit of normal, bilirubin ≤ 1.5x upper limit of normal~8. Adequate bone marrow function: Platelets ≥ 100,000 cells/mm3, hemoglobin \> 8.0 g/dL and ANC ≥ 1,500 cells/mm3~9. Adequate renal function with a creatinine clearance (based on Cockgroft-Gault formula) ≥ 45 mL/min~10. Ability to understand and the willingness to sign a written informed consent document~11. Able to swallow oral medication~Exclusion Criteria~Subjects must not meet any of the following criteria~1. Currently receiving any other investigational agents, a prior c-MET inhibitor, or crizotinib~2. Pregnant or breast feeding, because crizotinib can cause fetal harm~3. Uncontrolled and current illness including, but no limited to:~   * Ongoing or active infection~  * Symptomatic congestive heart failure~  * Unstable angina pectoris~  * Cardiac arrhythmia, or~  * Psychiatric illness/social situations that would limit compliance with study requirements~4. Presence of any of the following within the previous 3 months of treatment consent:~   * Myocardial infarction~  * Severe/unstable angina~  * Coronary/peripheral artery bypass graft~  * Congestive heart failure, or~  * Cerebrovascular accident including transient ischemia attack~5. History of active malignancy other than urothelial carcinoma within the prior 12 months of the date of treatment consent (except non-melanoma skin cancer or localized, treated prostate cancer)~6. Prolonged QT interval (QTc \> 480 msec), symptomatic bradycardia, ongoing cardiac dysrhythmias of CTCAE version 4.0 grade 2 ≥ or uncontrolled atrial fibrillation of any grade~7. Pulmonary disorder requiring supplemental oxygen or history of pulmonary fibrosis. Sleep apnea considered to be a sleep disorder (and not a pulmonary disorder) by the investigator will be allowed.~8. Subjects receiving any medications or substances that are strong inhibitors or inducers of CYP3A are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated list such as http://medicine.iupui.edu/clinpharm/ddis/table/aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the subject will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the subject is considering a new over-the-counter medicine or herbal product.~   * Medical condition requiring the use of strong CPY3A inhibitors, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, suboxone, telithromycin, troleandomycin, and voriconazole.~  * Use of grapefruit or grapefruit juice, which are considered strong CYP3A inhibitors.~  * Medical condition requiring the use of strong CYP3A inducers, including but not limited to carbamazepine, efavirenz, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's Wort, and troglitazone.~9. Receiving any medications that are CYP3A substrates with a narrow therapeutic range (alfentanil, cyclosporine, dihydroergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)~10. Subjects may be screened for study participation though may not begin study treatment:~    * Within 4 weeks of major surgery~   * Within 2 weeks of prior systemic therapy~   * Within 2 weeks of prior non-palliative radiotherapy~   * Within 48 hours of completion of palliative radiotherapy (≤ 10 fractions)~   * Until recovery of adverse events due to prior therapies to ≤ 1 (except alopecia)~11. Presence of untreated brain metastases or ≤ 6 months from prior treatment (from the time of enrollment), active neurologic symptoms or the use of prohibited medications in subjects with a history of brain metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): c-MET high (\> 50%), RON null (0-9%)
- Cohort 2 (Type: EXPERIMENTAL): c-MET + (10-100%), RON + (10-100%)
- Cohort 3 (Type: EXPERIMENTAL): c-MET null (0-9%), RON + (10-100%)

Based on this trial design, predict the completion outcome and termination type (if applicable).